摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 4-[(3,4,6,7,8,9-hexahydro-6,6,9,9-tetramethyl-1(2H)-phenazinon-2-yl)hydroxymethyl]benzoate | 177760-89-3

中文名称
——
中文别名
——
英文名称
methyl 4-[(3,4,6,7,8,9-hexahydro-6,6,9,9-tetramethyl-1(2H)-phenazinon-2-yl)hydroxymethyl]benzoate
英文别名
methyl 4-[hydroxy-(6,6,9,9-tetramethyl-1-oxo-3,4,7,8-tetrahydro-2H-phenazin-2-yl)methyl]benzoate
methyl 4-[(3,4,6,7,8,9-hexahydro-6,6,9,9-tetramethyl-1(2H)-phenazinon-2-yl)hydroxymethyl]benzoate化学式
CAS
177760-89-3
化学式
C25H30N2O4
mdl
——
分子量
422.524
InChiKey
ROBWTJJWHRIMCD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    31
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    89.4
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Mono- or polyenic carboxylic acid derivatives
    申请人:Eisai Co., Ltd.
    公开号:US06420363B1
    公开(公告)日:2002-07-16
    To provide novel compounds relating to retinoid which can substitute for retinoic acid used for preventing and treating several diseases and having antagonism against retinoid. Heterocyclic compounds represented by the general formula (1-I) or physiologically acceptable salts thereof: Z—(CR3═CR2)n—COOR1  (1-I) Compounds represented by the general formula (2-I) or physiologically acceptable salts thereof: The compounds according to the present invention exhibit extremely high ability to bind RARs and are effective for treating various kind of diseases such as abnormality in cornification and rheumatoid arthritis.
    提供与视黄醇相关的新化合物,可替代用于预防和治疗多种疾病的视黄酸,并具有对视黄醇的拮抗作用。所述杂环化合物由通式(1-I)表示,或其生理上可接受的盐:Z—(CR3═CR2)n—COOR1  (1-I)通式(2-I)表示的化合物或其生理上可接受的盐:根据本发明的化合物表现出极高的结合RARs的能力,并且对于治疗角化异常和类风湿性关节炎等各种疾病非常有效。
  • MONO- OR POLYENIC CARBOXYLIC ACID DERIVATIVE
    申请人:Eisai Co., Ltd.
    公开号:EP0790228A1
    公开(公告)日:1997-08-20
    To provide novel compounds relating to retinoid which can substitute for retinoic acid used for preventing and treating several diseases and having antagonism against retinoid. Heterocyclic compounds represented by the general formula (1-I) or physiologically acceptable salts thereof:         Z-(CR3=CR2)n-COOR1     (1-I) Compounds represented by the general formula (2-I) or physiologically acceptable salts thereof: The compounds according to the present invention exhibit extremely high ability to bind RARs and are effective for treating various kind of diseases such as abnormality in cornification and rheumatoid arthritis.
    提供与维甲酸有关的新型化合物,这些化合物可以替代用于预防和治疗多种疾病的维甲酸,并对维甲酸具有拮抗作用。 通式(1-I)代表的杂环化合物或其生理上可接受的盐类: Z-(CR3=CR2)n-COOR1 (1-I) 通式 (2-I) 所代表的化合物或其生理学上可接受的盐: 本发明的化合物具有极高的结合 RARs 的能力,可有效治疗各种疾病,如玉米粒化异常和类风湿性关节炎。
  • Heterocyclic compounds as retinoic acid receptor antagonists
    申请人:Eisai Co., Ltd.
    公开号:EP1065203A2
    公开(公告)日:2001-01-03
    Compounds represented by the general formula (2-I) or physiologically acceptable salts thereof: The compounds according to the present invention exhibit extremely high ability to bind RARs and are effective for treating various kind of diseases such as abnormality in cornification and rheumatoid arthritis.
    通式 (2-I) 所代表的化合物或其生理上可接受的盐类: 本发明的化合物与 RARs 的结合能力极强,可有效治疗各种疾病,如玉米粒化异常和类风湿性关节炎。
  • US5977125A
    申请人:——
    公开号:US5977125A
    公开(公告)日:1999-11-02
  • US6030964A
    申请人:——
    公开号:US6030964A
    公开(公告)日:2000-02-29
查看更多